Associate Track Chair: Assay Development and Screening

Saturday, February 3
0:00 AM - 11:59 PM

Ralph J. Garippa

Director, RNAi & CRISPR Core lab
Memorial Sloan-Kettering Cancer Center

Much of the work in my career has involved the co-development of several cutting-edge technologies that would serve to accelerate drug discovery processes. For example, 2D and 3D epi-fluorescent techniques; and the use of automated fluorescence microscopy for high throughput screening (HTS) of small molecules in 384 well formats.

The advent of gene perturbation technologies, most notably RNA interference and CRISPR-Cas9 gene editing technologies, have opened the door to unprecedented endeavors into the molecular genetics of cancer biology. We have employed techniques ranging from the monitoring of dynamic mass rearrangements via optical biosensors, to pooled mir30shRNA, arrayed siRNA, and genome-wide lentiviral Gecko CRISPR-Cas9 to seek and exploit novel molecular weaknesses in both liquid and solid cancers. Furthermore, we seek to deepen our understanding of: cancer stem cells in metastatic spread, 3D organoids as in vitro models of tumor progression, and the specific metabolic requirements of oncogene-driven cells.

Presentation(s):

Send Email for Ralph Garippa


Assets

Associate Track Chair: Assay Development and Screening



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Associate Track Chair: Assay Development and Screening